RNAVAX BIO
RNAVAX BIO is an Indian therapeutics company specializing in innovative mRNA technology to treat and prevent life-threatening diseases. With roots in Solan, Himachal Pradesh, and offices in Bangalore and Solan, the company focuses on developing RNA-based vaccines and health technologies to combat infectious diseases such as Dengue and Tuberculosis, especially in the Indian subcontinent. Their mission is to utilize cutting-edge genetic code solutions for rapid antigen production and improved health outcomes.
Industries
Nr. of Employees
medium (51-250)
Products
mRNA Vaccines
Vaccines that use messenger RNA to instruct cells to produce antigens, which then trigger an immune response to protect against infectious diseases.
Dengue Vaccine
An RNA-based vaccine aimed at providing immunity against the dengue virus, which affects millions of people annually.
Multi Drug Resistant TB Vaccine
An RNA-based vaccine designed to combat multi-drug resistant tuberculosis, a bacterial infection that primarily affects the lungs.
mRNA Vaccines
Vaccines that use messenger RNA to instruct cells to produce antigens, which then trigger an immune response to protect against infectious diseases.
Dengue Vaccine
An RNA-based vaccine aimed at providing immunity against the dengue virus, which affects millions of people annually.
Multi Drug Resistant TB Vaccine
An RNA-based vaccine designed to combat multi-drug resistant tuberculosis, a bacterial infection that primarily affects the lungs.
Services
R&D services to design and develop mRNA-based vaccines, including mRNA construct design, synthetic mRNA production, and preclinical antigen studies focused on infectious diseases.
R&D services to design and develop mRNA-based vaccines, including mRNA construct design, synthetic mRNA production, and preclinical antigen studies focused on infectious diseases.
Expertise Areas
- mRNA vaccine development
- Infectious disease vaccine programs (dengue, tuberculosis)
- Preclinical antigen design and synthesis
- mRNA delivery approaches
Key Technologies
- mRNA vaccine platform
- Synthetic mRNA synthesis
- mRNA delivery systems
- Antigen expression via mRNA
News & Updates
Johannesburg-based international research body Aurum Institute has said that a new tuberculosis treatment could reduce the pill needed from nine to three, lowering costs and improving adherence. The treatment will be rolled out in high TB prevalence countries including Ethiopia, Ghana, Kenya, Mozambique, and Zimbabwe.
Dr. Gaurav Sahay from OSU’s School of Pharmacy discusses research on messenger RNA vaccines, similar to those being developed for COVID-19.
Researchers discovered an antibody that controls the spread of dengue virus, which could lead to new treatments.
Vaccination is a key public health advance that can eradicate epidemics, with RNA vaccines being a promising new technology.
Johannesburg-based international research body Aurum Institute has said that a new tuberculosis treatment could reduce the pill needed from nine to three, lowering costs and improving adherence. The treatment will be rolled out in high TB prevalence countries including Ethiopia, Ghana, Kenya, Mozambique, and Zimbabwe.
Dr. Gaurav Sahay from OSU’s School of Pharmacy discusses research on messenger RNA vaccines, similar to those being developed for COVID-19.
Researchers discovered an antibody that controls the spread of dengue virus, which could lead to new treatments.
Vaccination is a key public health advance that can eradicate epidemics, with RNA vaccines being a promising new technology.